Literature DB >> 32972795

Mucormycosis with orbital compartment syndrome in a patient with COVID-19.

Amanda Werthman-Ehrenreich1.   

Abstract

During the current pandemic of COVID-19, a myriad of manifestations and complications has emerged and are being reported on. We are discovering patients with COVID-19 are at increased risk of acute cardiac injury, arrythmias, thromboembolic complications (pulmonary embolism and acute stroke), and secondary infection to name a few. I describe a novel case of COVID-19 in a previously healthy 33-year-old female who presented for altered mental status and proptosis. She was ultimately diagnosed with mucormycosis and orbital compartment syndrome, in addition to COVID-19. Early identification of these high morbidity conditions is key to allow for optimal treatment and improved outcomes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COVID-19; Mucormycosis; Orbital compartment syndrome

Mesh:

Year:  2020        PMID: 32972795      PMCID: PMC7493738          DOI: 10.1016/j.ajem.2020.09.032

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   4.093


  5 in total

1.  A multidisciplinary educational curriculum for the management of orbital compartment syndrome.

Authors:  Austin Fox; Ben Janson; Heather Stiff; Anthony Chung; Matthew Benage; Jon Van Heukelom; Thomas A Oetting; Erin M Shriver
Journal:  Am J Emerg Med       Date:  2019-12-09       Impact factor: 2.469

Review 2.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

3.  The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports.

Authors:  W Jeong; C Keighley; R Wolfe; W L Lee; M A Slavin; D C M Kong; S C-A Chen
Journal:  Clin Microbiol Infect       Date:  2018-07-21       Impact factor: 8.067

4.  Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis.

Authors:  Georgios Chamilos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

Review 5.  Disease Entities in Mucormycosis.

Authors:  Alexandra Serris; François Danion; Fanny Lanternier
Journal:  J Fungi (Basel)       Date:  2019-03-14
  5 in total
  104 in total

Review 1.  Mucormycosis in COVID-19: A systematic review of literature.

Authors:  Shivaraj Nagalli; Nidhi Shankar Kikkeri
Journal:  Infez Med       Date:  2021-12-10

Review 2.  CT Findings of COVID-19-associated Pulmonary Mucormycosis: A Case Series and Literature Review.

Authors:  Mandeep Garg; Nidhi Prabhakar; Valliappan Muthu; Shameema Farookh; Harsimran Kaur; Vikas Suri; Ritesh Agarwal
Journal:  Radiology       Date:  2021-08-31       Impact factor: 11.105

Review 3.  High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections.

Authors:  Kinal Bhatt; Arjola Agolli; Mehrie H Patel; Radhika Garimella; Madhuri Devi; Efrain Garcia; Harshad Amin; Carlos Domingue; Roberto Guerra Del Castillo; Marcos Sanchez-Gonzalez
Journal:  Discoveries (Craiova)       Date:  2021-03-31

4.  Hyperferritinemia and the Extent of Mucormycosis in COVID-19 Patients.

Authors:  Simple Bhadania; Neena Bhalodiya; Yashendra Sethi; Nirja Kaka; Swati Mishra; Neil Patel; Asad Ullah Wasim; Saumya S Joshi; Kenisha Shah
Journal:  Cureus       Date:  2021-12-21

5.  Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection.

Authors:  Vidya Krishna; Jaymin Morjaria; Rona Jalandari; Fatima Omar; Sundeep Kaul
Journal:  IDCases       Date:  2021-05-28

6.  The surge in Covid related mucormycosis.

Authors:  Somesh Chandra; Rakesh Rawal
Journal:  J Infect       Date:  2021-06-12       Impact factor: 38.637

7.  Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations.

Authors:  Nurettin Bayram; Cemal Ozsaygılı; Hafize Sav; Yucel Tekin; Medine Gundogan; Emine Pangal; Ayse Cicek; İbrahim Özcan
Journal:  Jpn J Ophthalmol       Date:  2021-05-31       Impact factor: 2.447

8.  Mucormycosis: An opportunistic pathogen during COVID-19.

Authors:  Iyer Mahalaxmi; Kaavya Jayaramayya; Dhivya Venkatesan; Mohana Devi Subramaniam; Kaviyarasi Renu; Padmavathi Vijayakumar; Arul Narayanasamy; Abilash Valsala Gopalakrishnan; Nachimuthu Senthil Kumar; Palanisamy Sivaprakash; Krothapalli R S Sambasiva Rao; Balachandar Vellingiri
Journal:  Environ Res       Date:  2021-07-06       Impact factor: 6.498

9.  Mucormycosis and COVID-19 an epidemic in a pandemic?

Authors:  Indrajit Banerjee; Jared Robinson; Mohammad Asim; Brijesh Sathian; Indraneel Banerjee
Journal:  Nepal J Epidemiol       Date:  2021-06-30

10.  Mucormycosis - An opportunistic infection in the aged immunocompromised individual: A reason for concern in COVID-19.

Authors:  Vivek P Chavda; Vasso Apostolopoulos
Journal:  Maturitas       Date:  2021-07-22       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.